PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Aurobindo Pharma gets UK MHRA Approval for Neutropenia Treatment Drug Dyrupeg

Aurobindo Pharma said that wholly owned step-down subsidiary CuraTeQ Biologics s.r.o. has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg.

Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a ‘biosimilar medicine’; this means that Dyrupeg is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the area of the regulatory agency

Dyrupeg is intended for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC).

This is CuraTeQ’s third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025.

Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company’s consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026